BIOMAT Database Logo BIOMAT Database Logo

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. 1995

J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Department d'Hematologie, Hôtel Dieu, Nantes, France.

The optimal source of stem cells is a controversial issue in the field of autologous stem cell transplantation. A comparison of autologous bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) after first remission induction treatment in multiple myeloma was made by a retrospective analysis of 132 transplants performed in 18 French Centers from 1984 to 1991 (81 autologous BMT, 51 PBSCT). The two groups differed in the median age (PBSCT 49 years; autologous BMT 55 years, P < 0.001), the duration of chemotherapy prior to transplantation, the interval between stem cell collection and transplantation, and in the conditioning regimen (more total body irradiation and higher doses of irradiation in the PBSCT group). The median time to neutrophil recovery was shorter in the PBSCT group (13 days vs. 20 days, P < 0.001), but the median time to platelet recovery did not differ significantly between PBSCT (26 days) and autologous BMT (22 days). There was no significant difference between the two groups regarding overall response rate (PBSCT 84%, autologous BMT 82%) and complete remission rate (PBSCT 37%, autologous BMT 36%). The actuarial relapse-free survival, time to treatment failure and overall survival were not significantly different. A case controlled study comparing 43 autologous BMT and 43 PBSCT matched for age and status at the time of transplantation did not show any advantage of PBSCT over autologous BMT in terms of immediate outcome, relapse-free survival, overall survival and time to treatment failure. Thus, in this retrospective analysis, the only significant benefit for PBSCT was reduced time to neutrophil recovery.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma.
January 1996, Cancer investigation,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Bone marrow and peripheral blood stem cell transplantation in multiple myeloma.
March 1997, Annals of oncology : official journal of the European Society for Medical Oncology,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Peripheral neuropathy after autologous blood stem cell transplantation for multiple myeloma.
February 1994, Leukemia,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.
October 2007, Bone marrow transplantation,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.
January 2014, BioMed research international,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma.
December 1996, Bone marrow transplantation,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy.
August 1991, Bone marrow transplantation,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
June 2022, American journal of hematology,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
January 2000, Haematologica,
J L Harousseau, and M Attal, and M Divine, and N Milpied, and G Marit, and V Leblond, and A M Stoppa, and J H Bourhis, and D Caillot, and M Boasson
Autologous peripheral blood stem cell transplantation in malignancies involving bone marrow.
March 1991, Haematologica,
Copied contents to your clipboard!